- Home
- VRNA vs CRL Comparison
VRNA vs CRL Comparison
Compare VRNA & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- CRL
- Stock Information
- Founded
- VRNA 2005
- CRL 1947
- Country
- VRNA United Kingdom
- CRL United States
- Employees
- VRNA N/A
- CRL N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- CRL Biotechnology: Commercial Physical & Biological Resarch
- Sector
- VRNA Health Care
- CRL Health Care
- Exchange
- VRNA Nasdaq
- CRL Nasdaq
- Market Cap
- VRNA 8.3B
- CRL 7.3B
- IPO Year
- VRNA 2017
- CRL 2000
- Fundamental
- Price
- VRNA $106.27
- CRL $151.56
- Analyst Decision
- VRNA Buy
- CRL Buy
- Analyst Count
- VRNA 11
- CRL 15
- Target Price
- VRNA $114.10
- CRL $186.64
- AVG Volume (30 Days)
- VRNA 1.3M
- CRL 734.6K
- Earning Date
- VRNA 11-03-2025
- CRL 11-05-2025
- Dividend Yield
- VRNA N/A
- CRL N/A
- EPS Growth
- VRNA N/A
- CRL N/A
- EPS
- VRNA N/A
- CRL N/A
- Revenue
- VRNA $221,673,000.00
- CRL $4,028,615,000.00
- Revenue This Year
- VRNA $896.59
- CRL N/A
- Revenue Next Year
- VRNA $77.56
- CRL $2.16
- P/E Ratio
- VRNA N/A
- CRL N/A
- Revenue Growth
- VRNA N/A
- CRL N/A
- 52 Week Low
- VRNA $27.54
- CRL $91.86
- 52 Week High
- VRNA $106.45
- CRL $230.02
- Technical
- Relative Strength Index (RSI)
- VRNA 68.40
- CRL 50.53
- Support Level
- VRNA $106.15
- CRL N/A
- Resistance Level
- VRNA $106.42
- CRL $159.78
- Average True Range (ATR)
- VRNA 0.19
- CRL 5.65
- MACD
- VRNA -0.17
- CRL -6.76
- Stochastic Oscillator
- VRNA 76.32
- CRL 90.48
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.